PIII - P3 Health Partners Inc. Stock Price, Fair Value and News

0.51USD-0.01 (-1.92%)Market Closed

Market Summary

USD0.51-0.01

Market Closed

-1.92%

PIII Stock Price

View Fullscreen

PIII RSI Chart

PIII Valuation

Market Cap

48.4M

Price/Earnings (Trailing)

-0.84

Price/Sales (Trailing)

0.04

EV/EBITDA

-1.07

Price/Free Cashflow

-0.62

PIII Price/Sales (Trailing)

PIII Profitability

EBT Margin

-14.51%

Return on Equity

-40.65%

Return on Assets

-6.71%

Free Cashflow Yield

-160.88%

PIII Fundamentals

PIII Revenue

Revenue (TTM)

1.3B

Rev. Growth (Yr)

34.33%

Rev. Growth (Qtr)

20.29%

PIII Earnings

Earnings (TTM)

-57.8M

Earnings Growth (Yr)

72.92%

Earnings Growth (Qtr)

-91.5%

Breaking Down PIII Revenue

Last 7 days

6.1%

Last 30 days

-47.5%

Last 90 days

-54.8%

Trailing 12 Months

-54.0%

How does PIII drawdown profile look like?

PIII Financial Health

Current Ratio

0.55

Debt/Equity

0.76

Debt/Cashflow

-0.7

PIII Investor Care

Shares Dilution (1Y)

128.21%

Diluted EPS (TTM)

-0.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.1B	1.1B	1.2B	1.3B
2022	766.9M	861.1M	955.3M	1.0B
2021	517.6M	549.6M	576.9M	578.6M
2020	230.8M	315.7M	400.6M	485.5M
2019	0	0	0	145.9M
2018	0	0	0	87.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of P3 Health Partners Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 09, 2024	bacchus amir	acquired	-	-	287,118	chief medical officer
Jan 09, 2024	abdou sherif	acquired	-	-	483,868	chief executive officer
Dec 31, 2023	bacchus amir	sold (taxes)	-404,836	1.41	-287,118	chief medical officer
Dec 31, 2023	abdou sherif	sold (taxes)	-682,254	1.41	-483,868	chief executive officer
Oct 23, 2023	wasson gregory d	acquired	-	-	216,561	-
Oct 23, 2023	tolan mary a	acquired	-	-	216,561	-
Oct 23, 2023	price thomas edmunds	acquired	-	-	216,561	-
Oct 23, 2023	leisure lawrence b.	acquired	-	-	216,561	-
Oct 23, 2023	kazarian gregory n.	acquired	-	-	216,561	-
Oct 23, 2023	park jeffrey g	acquired	-	-	216,561	-

Which funds bought or sold PIII recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	Mesirow Financial Investment Management, Inc.	sold off	-100	-21,150	-	-%
Apr 11, 2024	Tuttle Capital Management, LLC	unchanged	-	-413	831	0.01%
Apr 11, 2024	SANDERS MORRIS HARRIS LLC	new	-	2,800	2,800	-%
Apr 11, 2024	SANDERS MORRIS HARRIS LLC	unchanged	-	-41,043	126,688	0.02%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-4,121	96,859	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	unchanged	-	-751	666	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-39.45	-1,588,050	2,200,520	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-64,016	-	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	-1,336	28,592	-%

Are Funds Buying or Selling PIII?

Are funds buying PIII calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PIII

No. of Funds

Unveiling P3 Health Partners Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 27, 2024	ameriprise financial inc	4.72%	5,441,489	SC 13G/A
Feb 14, 2024	ameriprise financial inc	4.72%	5,441,489	SC 13G/A
Feb 13, 2024	vanguard group inc	1.35%	1,560,655	SC 13G/A
Feb 12, 2024	lmr partners llp	2.2%	2,546,924	SC 13G/A
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Nov 03, 2023	abdou sherif	2.5%	7,907,484	SC 13D/A
Jun 12, 2023	fmr llc	-	0	SC 13G/A
Apr 21, 2023	chicago pacific founders ugp, llc	34.71%	110,415,418	SC 13D/A
Apr 19, 2023	leavitt equity partners ii, l.p.	14.9%	9,070,678	SC 13D/A
Apr 14, 2023	bacchus amir	8.6%	20,989,518	SC 13D/A

Recent SEC filings of P3 Health Partners Inc.

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 12, 2024	8-K	Current Report
Mar 12, 2024	NT 10-K	NT 10-K
Feb 27, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	SC 13G/A	Major Ownership Report
Jan 25, 2024	4	Insider Trading
Jan 25, 2024	4	Insider Trading

Peers (Alternatives to P3 Health Partners Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	448.5B	371.6B	0.25%	1.54%	20.04	1.21	14.64%	11.24%
CI	103.1B	195.3B	0.42%	40.12%	19.19	0.53	8.17%	-20.79%
CVS	86.2B	357.8B	-11.34%	-4.48%	10.32	0.24	10.95%	93.52%
HCA	84.5B	65.0B	-5.91%	10.40%	16.12	1.3	7.86%	-7.11%
CNC	40.6B	154.0B	-1.73%	14.56%	15.01	0.26	6.54%	124.79%
DVA	11.7B	12.1B	-1.16%	54.10%	16.99	0.97	4.57%	23.40%
UHS	11.4B	14.3B	-10.74%	15.10%	15.93	0.8	6.59%	6.24%
MID-CAP
CHE	9.3B	2.3B	-6.84%	6.65%	34.25	4.12	6.06%	9.17%
ACHC	6.5B	2.9B	-8.12%	-4.65%	-301.31	2.23	12.20%	-107.93%
AMN	2.2B	3.8B	-11.58%	-36.32%	10.27	0.57	-27.73%	-52.50%
AMEH	2.1B	1.4B	-5.67%	-3.33%	34.17	1.5	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-9.80%	-16.99%	24.6	1.45	11.31%	35.83%
BKD	1.3B	3.0B	2.33%	54.33%	-6.94	0.44	6.74%	20.73%
BEAT	54.5M	-	-7.94%	-8.37%	-3.72	-	-	-12.94%
AMS	18.9M	21.3M	14.02%	5.61%	35.51	0.89	8.00%	-62.25%

P3 Health Partners Inc. News

Latest updates

P3 Health Partners Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Revenue	20.3%	346,861,000	288,351,000	329,086,000	302,077,000	258,213,000	248,260,000	269,454,000	273,544,000	200,037,831	126,531,662	156,185,955	144,586,444	151,297,940	124,877,011	128,840,991	-	-	-	-
Operating Expenses	27.6%	411,121,000	322,171,000	350,119,000	350,894,000	794,760,000	308,271,000	1,181,641,000	325,712,000	7,000,000	188,506,629	184,309,497	170,557,507	164,286,370	2,286	142,355,570	-	-	-	-
S&GA Expenses	10.2%	721,000	654,000	857,000	1,001,000	1,705,000	1,118,000	1,408,000	865,000	-	21,629,657	491,418	356,501	270,241	2,286	278,663	-	-	-	-
EBITDA Margin	81.7%	-0.09	-0.49	-0.53	-1.37	-1.41	-0.16	-0.18	-0.20	-0.23	-0.27	-0.06	-0.06	-0.06	-0.07	-0.11	-0.14	-0.19	-0.30	-
Interest Expenses	-1.1%	-4,046,000	-4,002,000	-3,851,000	-4,086,000	-2,986,000	-2,963,000	-2,700,000	-2,755,000	-	-2,800,815	-2,529,133	-2,369,764	-2,124,286	4,344,439	-2,316,579	-	-	-	-
Income Taxes	328.9%	1,767,000	412,000	226,000	290,000	1,862,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-82.6%	-67,340,000	-36,877,000	-27,356,000	-52,158,000	-530,470,000	-65,329,000	-903,106,000	-60,790,000	-	-60,230,517	-32,054,361	-29,464,410	-24,650,712	-	-	-	-	-	-
EBT Margin	73.6%	-0.15	-0.55	-0.59	-1.44	-1.49	-0.15	-0.17	-0.19	-0.22	-0.25	-0.05	-0.06	-0.06	-0.06	-0.10	-0.13	-0.18	-0.29	-
Net Income	-91.5%	-25,462,000	-13,296,000	-9,816,000	-9,199,000	-94,027,000	-11,173,000	-154,350,000	-10,577,000	-	61,364,359	-32,054,361	-29,464,410	-24,650,712	-2,286	-875,560	-2,774,562	1,550,953	-	-
Net Income Margin	57.5%	-0.05	-0.11	-0.11	-0.25	-0.26	-0.03	-0.03	-0.03	-0.04	-0.04	-0.15	-0.10	-0.04	0.01	-0.10	-0.13	-0.18	-0.29	-0.50
Free Cashflow	-96.5%	-15,666,000	-7,973,000	-30,030,000	-24,186,000	-31,904,000	-21,859,000	-45,836,000	-28,653,000	37,941,032	37,941,032	-6,802,469	-22,237,214	-13,777,897	-18,644,652	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-4.0%	861	897	909	867	877	1,383	1,444	2,357	2,364	317	79.00	317	233	149	66.00
Current Assets	-7.6%	166	180	172	109	101	124	171	213	200	0.00	54.00	1.00	79.00	0.00	52.00
Cash Equivalents	-30.9%	36.00	53.00	60.00	7.00	18.00	35.00	64.00	111	141	0.00	4.00	16.00	22.00	0.00	33.00
Net PPE	-7.2%	9.00	9.00	10.00	9.00	9.00	10.00	8.00	8.00	8.00	-	8.00	-	-	6.00	4.00
Goodwill	-	-	-	-	-	-	463	458	1,310	1,310	1,278	6.00	3.00	3.00	1.00	1.00
Liabilities	7.9%	427	396	378	396	354	331	329	342	300	35.00	203	16.00	6.00	40.00	74.00
Current Liabilities	12.0%	299	267	250	270	242	227	229	234	199	21.00	119	0.00	0.00	0.00	55.00
Short Term Borrowings	-	-	-	-	-	-	-	1.00	2.00	4.00	-	-	-	-	-	-
Long Term Debt	0.1%	108	108	108	108	94.00	80.00	80.00	80.00	80.00	-	59.00	-	45.00	45.00	15.00
LT Debt, Current	-	-	-	-	-	-	-	-	0.00	0.00	-	0.00	-	0.00	0.00	2.00
LT Debt, Non Current	0.1%	108	108	108	108	94.00	80.00	80.00	80.00	80.00	-	59.00	-	45.00	45.00	15.00
Shareholder's Equity	-24.4%	142	188	-	-	6.00	78.00	109	263	274	284	-	5.00	5.00	0.00	-
Retained Earnings	-7.4%	-367	-341	-328	-318	-309	-215	-204	-50.00	-39.42	-34.19	-0.97	-184	10.00	0.00	-85.17
Additional Paid-In Capital	-3.8%	509	530	192	316	315	294	313	313	313	-	-	-10.71	-0.18	0.00	-
Accumulated Depreciation	-	5.00	-	-	-	3.00	2.00	1.00	1.00	0.00	-	-	-	-	2.00	-
Shares Outstanding	7.8%	95.00	88.00	107	42.00	42.00	42.00	42.00	42.00	-	-	68.00	-	-	66.00	48.00
Float	-	-	-	117	-	-	-	93.00	-	-	-	-	248	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Cashflow From Operations	-109.3%	-15,878	-7,586	-28,842	-23,722	-31,954	-20,977	-45,312	-27,776	-	38,241	-5,695	-21,010	-13,121	-17,950	-	-	-	-	-
Share Based Compensation	-23.6%	1,720	2,251	1,031	977	2,193	1,784	3,716	11,711	-	2,322	355	564	461	-203	-	-	-	-	-
Cashflow From Investing	154.8%	212	-387	-1,188	-464	50.00	-6,382	-252	-1,149	-	-308,365	-6,145	-1,008	-729	-1,269	-	-	-	-	-
Cashflow From Financing	-876.7%	-840	-86.00	87,156	14,102	15,000	-1,179	-1,239	-1,207	-	305,266	-22.59	12,536	-22.22	180	-	-	-	-	-

PIII Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
OPERATING REVENUE:
TOTAL OPERATING REVENUE	$ 1,266,375	$ 1,049,471
OPERATING EXPENSE:
Medical expense	1,234,740	1,057,224
Premium deficiency reserve	(12,705)	(11,461)
Corporate, general and administrative expense	122,362	157,284
Sales and marketing expense	3,233	5,096
Depreciation and amortization	86,675	87,289
Goodwill impairment	0	1,314,952
TOTAL OPERATING EXPENSE	1,434,305	2,610,384
OPERATING LOSS	(167,930)	(1,560,913)
OTHER INCOME (EXPENSE):
Interest expense, net	(15,985)	(11,404)
Mark-to-market of stock warrants	433	9,865
Other	(249)	2,757
TOTAL OTHER (EXPENSE) INCOME	(15,801)	1,218
LOSS BEFORE INCOME TAXES	(183,731)	(1,559,695)
PROVISION FOR INCOME TAXES	(2,695)	(1,862)
NET LOSS	(186,426)	(1,561,557)
LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST	(128,653)	(1,291,430)
NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST	$ (57,773)	$ (270,127)
NET LOSS PER SHARE (Note 15):
Basic (in dollars per share)	$ (0.61)	$ (6.50)
Diluted (in dollars per share)	$ (0.63)	$ (6.50)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 15):
Basic (in shares)	94,889	41,579
Diluted (in shares)	294,590	41,579
Capitated revenue
OPERATING REVENUE:
TOTAL OPERATING REVENUE	$ 1,252,309	$ 1,034,800
Other patient service revenue
OPERATING REVENUE:
TOTAL OPERATING REVENUE	$ 14,066	$ 14,671

PIII Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

CURRENT ASSETS:

Cash

$ 36,320

$ 17,537

Restricted cash

4,614

920

Health plan receivable, net of allowance for credit losses of $150 and $0, respectively

118,497

72,092

Clinic fees, insurance and other receivable

2,973

7,500

Prepaid expenses and other current assets

3,613

2,643

TOTAL CURRENT ASSETS

166,017

100,692

Property and equipment, net

8,686

8,839

Intangible assets, net

666,733

751,050

Other long-term assets

19,531

15,990

TOTAL ASSETS

^[1]

860,967

876,571

CURRENT LIABILITIES:

Accounts payable

8,663

11,542

Accrued expenses and other current liabilities

36,884

16,647

Accrued payroll

3,506

8,224

Health plan settlements payable

34,992

13,608

Claims payable

178,009

151,207

Premium deficiency reserve

13,670

26,375

Accrued interest

23,648

14,061

TOTAL CURRENT LIABILITIES

299,372

241,664

Operating lease liability

13,622

11,516

Warrant liabilities

1,085

1,517

Contingent consideration

4,907

4,794

Long-term debt, net

108,319

94,421

TOTAL LIABILITIES

^[1]

427,305

353,912

COMMITMENTS AND CONTINGENCIES (Note 16 and Note 20)

MEZZANINE EQUITY:

Redeemable non-controlling interest

291,532

516,805

STOCKHOLDERS’ EQUITY:

Additional paid in capital

509,442

315,375

Accumulated deficit

(367,344)

(309,545)

TOTAL STOCKHOLDERS’ EQUITY

142,130

5,854

TOTAL LIABILITIES, MEZZANINE EQUITY, and STOCKHOLDERS’ EQUITY

860,967

876,571

Class A Common Stock

STOCKHOLDERS’ EQUITY:

Common stock

Class V Common Stock

STOCKHOLDERS’ EQUITY:

Common stock

$ 20

[1]

The Company’s consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 22: Variable Interest Entities, P3 LLC is itself a VIE. P3 LLC represents substantially all the assets and liabilities of the Company. As a result, the language and numbers below refer only to VIEs held at the P3 LLC level. The consolidated balance sheets include total assets that can be used only to settle obligations of P3 LLC’s consolidated VIEs totaling $8.6 million and $3.1 million as of December 31, 2023 and 2022, respectively, and total liabilities of P3 LLC’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaled $13.6 million and $9.9 million as of December 31, 2023 and 2022, respectively. These VIE assets and liabilities do not include $44.2 million and $33.0 million of net amounts due to affiliates as of December 31, 2023 and 2022, respectively, as these are eliminated in consolidation and not presented within the consolidated balance sheets.

About P3 Health Partners Inc.

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.

CEO	Dr. Sherif Abdou F.A.C.E.P., FACP, M.D.
WEBSITE	https://p3hp.org
INDUSTRY	Healthcare Plans
EMPLOYEES	600

P3 Health Partners Inc. Frequently Asked Questions

What is the ticker symbol for P3 Health Partners Inc.? What does PIII stand for in stocks?

PIII is the stock ticker symbol of P3 Health Partners Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of P3 Health Partners Inc. (PIII)?

As of Mon Apr 22 2024, market cap of P3 Health Partners Inc. is 49.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PIII stock?

You can check PIII's fair value in chart for subscribers.

What is the fair value of PIII stock?

You can check PIII's fair value in chart for subscribers. The fair value of P3 Health Partners Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of P3 Health Partners Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PIII so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is P3 Health Partners Inc. a good stock to buy?

The fair value guage provides a quick view whether PIII is over valued or under valued. Whether P3 Health Partners Inc. is cheap or expensive depends on the assumptions which impact P3 Health Partners Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PIII.

What is P3 Health Partners Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, PIII's PE ratio (Price to Earnings) is -0.85 and Price to Sales (PS) ratio is 0.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PIII PE ratio will change depending on the future growth rate expectations of investors.